Theratechnologies Sets $118k Yearly Price For HIV Biologic Trogarzo

The company's monoclonal antibody for multidrug resistant HIV-1 patients licensed from TaiMed will launch soon.

Digital illustration of HIV Virus in Blood Stream in color background

Montreal-basedTheratechnologies Inc.has set a $118,000 annual list price for the just-approved HIV-1 biologic Trogarzo (ibalizumab-uiyk) in the US, though it expects to net 30% less than that after rebates, and plans to launch in six weeks.

The US FDA approved the drug March 6 for multidrug resistant HIV (MDR HIV), that is people with HIV-1 who...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from New Products

More from Scrip